Denosumab - Next gen biotech blockbusters

Drug: Denosumab
Company: Amgen

Scoop: Denosumab is a fully-human monoclonal antibody which Amgen is studying for a number of indications, including osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, multiple myeloma and breast cancer. The company has reported results from several Phase III studies, including one in which denosumab performed better than Fosomax in a head-to-head trial.

Amgen hopes to get a cut of the $7 billion osteoporosis market with the drug's approval, and according to one analyst, the drug "could achieve sales topping $2 billion a year if and when approved for both osteoporosis and cancer patients." That would go a long way in turning around the company's fortunes after anemia drug sales took a hit last year. And denosumab is even more important to the company, as it's the only potential blockbuster nearing FDA approval.

Denosumab - Next gen biotech blockbusters
Read more on

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.